ArticleInflammopharmacology2025
Endotoxin (lipopolysaccharide)-induced inflammation in albino rat and macrophages (RAW 264.7): Piper mullesua leaf extract as promising therapeutic against inflammatory pathophysiology via SOCS1 activation and phospho-NF-κB/JAK1/STAT1 inhibition.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The present investigation has been attempted for scientifically validating the traditional uses of Piper mullesua against inflammatory pathophysiology using both in vivo (albino rats) and in vitro (macrophage cells, RAW 264.7) models of inflammation caused by an endotoxin (lipopolysaccharide, LPS). Oral gavaging with PMHAE, hydroalcoholic extract of Piper mullesua leaves, dose-responsively (50, 100, or 200 mg/kg BW, 14 days) restored any alteration in the concentration of serum inflammatory cytokines, IL-6, TNF-α, IL-4, and IL-10 and decreased prostaglandin (PGE2) and nitrite count in rats injected (i.p.) with LPS (10 mg/kg BW). PMHAE supplementation (5, 10, or 20 µg/mL) further attenuated MCP-1, IL-6, and TNF-α, and increased IL-10 and IL-4 secretion and mRNA expression in LPS-treated (50 ng/mL) macrophages. PMHAE also enhanced phagocytic potential while attenuated ROS counts in LPS-treated cells. Additionally, PMHAE supplementation increased SOCS1 protein expression and decreased NF-κB phosphorylation (Serine 536), along with the expression of JAK1/STAT1 proteins in LPS-treated cells. Treatment with PMHAE did not cause any toxicity to animals and cultured cells. Phytochemical analysis (LC-MS/GC-MS) revealed various compounds, including piperine, piperlongumine, pipernonaline, phytol, methyl eugenol, and pinene, contributing to anti-inflammatory potential of PMHAE. These findings suggested Piper mullesua as a safe, effective, and potential anti-inflammatory avenue for therapeutic exploration in inflammatory pathophysiology.
Indexed as
Identifiers
40146441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.